• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00470.

作者信息

Pradere Benjamin, Basile Giuseppe, Seisen Thomas

机构信息

Department of Urology UROSUD, La Croix Du Sud Hospital, Quint Fonsegrives, France; Department of Urology, Comprehensive Cancer Center, Medical University of Vienna, Vienna, Austria.

Department of Urology, IRCCS San Raffaele Hospital, Milan, Italy.

出版信息

Eur Urol. 2023 Apr;83(4):e105-e106. doi: 10.1016/j.eururo.2022.12.036. Epub 2023 Jan 28.

DOI:10.1016/j.eururo.2022.12.036
PMID:36717285
Abstract
摘要

相似文献

1
Re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol. In press. https://doi.org/10.1200/JCO.22.00470.回复：玛丽亚·S·林德格伦、埃里克·汉森、内斯恩·阿扎维、安娜·M·尼尔森、拉尔斯·迪尔斯约特、约根·B·延森。DaBlaCa - 13研究：丝裂霉素短期强化化疗切除术治疗非肌层浸润性膀胱癌的肿瘤学结局：一项随机对照试验的主要结局。《临床肿瘤学杂志》。即将发表。https://doi.org/10.1200/JCO.22.00470
Eur Urol. 2023 Apr;83(4):e105-e106. doi: 10.1016/j.eururo.2022.12.036. Epub 2023 Jan 28.
2
Reply to Benjamin Pradere, Giuseppe Basile, and Thomas Seisen's Letter to the Editor re: Maria S. Lindgren, Eric Hansen, Nessn Azawi, Anna M. Nielsen, Lars Dyrskjøt, Jørgen B. Jensen. DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial. J Clin Oncol 2023;41:2,206-11.回复本杰明·普拉德雷、朱塞佩·巴西莱和托马斯·塞森致编辑的信，信中涉及：玛丽亚·S·林德格伦、埃里克·汉森、内斯恩·阿扎维、安娜·M·尼尔森、拉尔斯·迪尔斯约特、约根·B·延森。DaBlaCa - 13研究：丝裂霉素短期强化化疗切除术治疗非肌层浸润性膀胱癌的肿瘤学结局：一项随机对照试验的主要结局。《临床肿瘤学杂志》2023年；41卷：2206 - 2211页。
Eur Urol. 2023 Apr;83(4):e107-e108. doi: 10.1016/j.eururo.2023.01.015. Epub 2023 Jan 28.
3
Re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62.回复：玛丽亚·S·林德格伦、彼得·比、内斯恩·阿扎维等。DaBlaCa - 13研究：非肌层浸润性膀胱癌短期强化化疗切除与标准辅助膀胱内灌注——一项随机对照试验。《欧洲泌尿外科杂志》2020年；78卷：856 - 62页。
Eur Urol. 2021 May;79(5):e135-e136. doi: 10.1016/j.eururo.2021.01.034. Epub 2021 Feb 13.
4
Reply to Claudia Signorini and Massimo Maffezzini's Letter to the Editor re: Maria S. Lindgren, Peter Bue, Nessn Azawi, et al. The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomized Controlled Trial. Eur Urol 2020;78:856-62.
Eur Urol. 2021 May;79(5):e137. doi: 10.1016/j.eururo.2021.02.001. Epub 2021 Feb 13.
5
Re: DaBlaCa-13 Study: Oncological Outcome of Short-term, Intensive Chemoresection with Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.回复：DaBlaCa - 13研究：丝裂霉素短期强化化疗切除术治疗非肌层浸润性膀胱癌的肿瘤学结局：一项随机对照试验的主要结局
Eur Urol. 2023 Nov;84(5):512-513. doi: 10.1016/j.eururo.2023.05.028. Epub 2023 Jun 1.
6
DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.DaBlaCa - 13研究：丝裂霉素短期强化化疗切除术治疗非肌层浸润性膀胱癌的肿瘤学结局：一项随机对照试验的主要结局
J Clin Oncol. 2023 Jan 10;41(2):206-211. doi: 10.1200/JCO.22.00470. Epub 2022 Oct 12.
7
Erratum: DaBlaCa-13 Study: Oncological Outcome of Short-Term, Intensive Chemoresection With Mitomycin in Nonmuscle Invasive Bladder Cancer: Primary Outcome of a Randomized Controlled Trial.
J Clin Oncol. 2023 Mar 10;41(8):1633-1634. doi: 10.1200/JCO.22.02889. Epub 2023 Jan 25.
8
The DaBlaCa-13 Study: Short-term, Intensive Chemoresection Versus Standard Adjuvant Intravesical Instillations in Non-muscle-invasive Bladder Cancer-A Randomised Controlled Trial.DaBlaCa-13 研究：非肌肉浸润性膀胱癌短期强化化学切除术与标准辅助膀胱内灌注治疗的随机对照试验。
Eur Urol. 2020 Dec;78(6):856-862. doi: 10.1016/j.eururo.2020.07.009. Epub 2020 Jul 28.
9
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复：沈伟、亚伦·普伦德加斯特、夏洛特·阿克曼等。中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的比较（HIVEC-II）：一项2期、开放标签、随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003
Eur Urol. 2023 Feb;83(2):e47. doi: 10.1016/j.eururo.2022.10.027. Epub 2022 Nov 17.
10
Re: Wei Shen Tan, Aaron Prendergast, Charlotte Ackermann, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non-muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003.回复：沈伟、亚伦·普伦德加斯特、夏洛特·阿克曼等人。中危非肌层浸润性膀胱癌患者辅助膀胱内热化疗与单纯化疗的比较（HIVEC-II）：一项2期开放标签随机对照试验。《欧洲泌尿外科杂志》。即将发表。https://doi.org/10.1016/j.eururo.2022.08.003
Eur Urol. 2023 Feb;83(2):e56-e57. doi: 10.1016/j.eururo.2022.09.035. Epub 2022 Nov 10.